Meeting
2017 Gastrointestinal Cancers Symposium
A phase I study of ADH-1 with cisplatin (Cisp) & gemcitabine (Gem) in patients (Pts) with unresectable or metastatic pancreatic and biliary tract cancers.
Authors
Lyudmyla Derby Berim
Univ of Nebraska, Omaha, NE
Lyudmyla Derby Berim , Beth M Kos , Ruby Evande , Jane L Meza , Valerie Shostrom , James K. Schwarz , Jean L. Grem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01825603
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 306)
DOI
10.1200/JCO.2017.35.4_suppl.306
Abstract #
306
Poster Bd #
D20
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.
First Author: Suguru Yamada
Poster
2017 Gastrointestinal Cancers Symposium
The phase I study of concurrent chemoradiotherapy using a combination of gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer: Update.
First Author: Tatsuya Ioka
Poster
2024 ASCO Annual Meeting
Safety of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in patients (pts) with biliary tract cancer with peritoneal metastases.
First Author: Daneng Li
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer.
First Author: Mohamed Bouattour